Liu Lili, Lu Liqin, Zheng Aihong, Xie Jiansheng, Xue Qian, Wang Fuwei, Wang Xiao, Zhou Hongying, Tong Xiangmin, Li Yaqing, Zhu Xiuming, Wu Guoqing
Department of Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Department of Oncology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
Oncotarget. 2017 Feb 21;8(8):13666-13677. doi: 10.18632/oncotarget.14623.
Hepatocellular carcinoma (HCC) has a high recurrence rate, and patients exhibit poor survival mainly because intrahepatic metastasis is common. We previously reported that let-7c down-regulation is significantly associated with poor differentiation level in HCC. In the present study, we demonstrate that miR-199a-5p and let-7c are frequently down-regulated in HCC cells and tissues, and low expression of miR-199a-5p is correlated with tumor size, liver envelope invasion. Furthermore, miR-199a-5p and let-7c cooperatively inhibit HCC cell migration and invasion in vitro. MAP4K3 is identified as the direct target of miR-199a-5p and let-7c and this regulation is further confirmed by luciferase reporter assays and Western blotting. In addition, MAP4K3 functions as a metastasis promoter since the results demonstrate that MAP4K3 could promote HCC cell migration and invasion. We also find that miR-199a-5p and let-7c increase the sensitivity of HCC cells to sorafenib.
We report that miR-199a-5p and let-7c cooperatively and efficiently inhibit HCC cell migration and invasion by targeting the metastasis promoter MAP4K3 and MAP4K3-mediated drug sensitization, suggesting that the use of miRNAs and sorafenib in combination therapy may be a powerful approach to the treatment of HCC.
肝细胞癌(HCC)复发率高,患者生存率低,主要原因是肝内转移常见。我们之前报道过,let-7c下调与HCC的低分化程度显著相关。在本研究中,我们证明miR-199a-5p和let-7c在HCC细胞和组织中经常下调,miR-199a-5p低表达与肿瘤大小、肝包膜侵犯相关。此外,miR-199a-5p和let-7c在体外协同抑制HCC细胞迁移和侵袭。MAP4K3被鉴定为miR-199a-5p和let-7c的直接靶点,荧光素酶报告基因检测和蛋白质印迹进一步证实了这种调控。此外,MAP4K3起转移促进因子的作用,因为结果表明MAP4K3可促进HCC细胞迁移和侵袭。我们还发现miR-199a-5p和let-7c增加了HCC细胞对索拉非尼的敏感性。
我们报道miR-199a-5p和let-7c通过靶向转移促进因子MAP4K3及MAP4K3介导的药物致敏作用,协同有效地抑制HCC细胞迁移和侵袭,提示联合使用miRNAs和索拉非尼进行治疗可能是治疗HCC的有效方法。